CDKN2A/p16 in ependymomas
作者： Simona Bortolotto , Loredana Chiadò-Piat , Paola Cavalla , Ivana Bosone , Alessandro Mauro
关键词:
摘要: Sixteen cases of ependymoma were studied for CDKN2A/p16 inactivation by immunohistochemistry using a p16 monoclonal antibody, homozygous deletion (HD) assay and 5′CpG promoter methylation (methylation-specific PCR). Three out 16 immuno-negative: two corresponded to grade II ependymomas one III. The latter ependymoma, characterized high Ki-67/MIB-1 LI, was the only whole series show CDKN2A HD. No found in immuno-negative without Alternative mechanisms, such as point mutations or alterations post-translational regulation, may be responsible inactivation. Since our just eight anaplastic showed negative immunostaining HD, p16/CDKN2A not play an important role malignant transformation ependymomas.
springer.com
elsevier.com
sci-hub.se 参考文章(24)
Helena Miettinen, Juha Kononen, Pauli Sallinen, Hannu Alho, Pauli Helen, Heikki Helin, Hannu Kalimo, Leo Paljärvi, Jorma Isola, Hannu Haapasalo, CDKN2/p16 predicts survival in oligodendrogliomas : comparison with astrocytomas Journal of Neuro-oncology. ,vol. 41, pp. 205- 211 ,(1999) , 10.1023/A:1006185220369
B. Tycko, M. Sisti, Luwa Yuan, T. Moulton, Ghassan Samara, J. Bruce, Raj Desai, Wai-Yee Chung, MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. American Journal of Pathology. ,vol. 146, pp. 613- 619 ,(1995)
G Reifenberger, K Ichimura, V P Collins, E E Schmidt, CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Research. ,vol. 54, pp. 6321- 6324 ,(1994)
Joseph F. Costello, Mitchel S. Berger, H-J. Su Huang, Webster K. Cavenee, Silencing of p16/CDKN2 Expression in Human Gliomas by Methylation and Chromatin Condensation Cancer Research. ,vol. 56, pp. 2405- 2410 ,(1996)
Andreas von Deimling, Jimmy T. Efird, John W. Henson, David N. Louis, Yasuhiro Ono, Keisuke Ueki, CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated Cancer Research. ,vol. 56, pp. 150- 153 ,(1996)
Gaetano Finocchiaro, Cristiana Giani, Mutation Rate of the CDKN2 Gene in Malignant Gliomas Cancer Research. ,vol. 54, pp. 6338- 6339 ,(1994)
EE Schmidt, K Ichimura, KR Messerle, HM Goike, VP Collins, Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours British Journal of Cancer. ,vol. 75, pp. 2- 8 ,(1997) , 10.1038/BJC.1997.2
Adrian Merlo, James G. Herman, Li Mao, Daniel J. Lee, Edward Gabrielson, Peter C. Burger, Stephen B. Baylin, David Sidransky, 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine. ,vol. 1, pp. 686- 692 ,(1995) , 10.1038/NM0795-686
T. Tominaga, T. Kayama, T. Kumabe, Y. Sonoda, T. Yoshimoto, Anaplastic ependymomas: Clinical features and tumour suppressor gene p53 analysis Acta Neurochirurgica. ,vol. 135, pp. 163- 170 ,(1995) , 10.1007/BF02187763
J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin, S. B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proceedings of the National Academy of Sciences of the United States of America. ,vol. 93, pp. 9821- 9826 ,(1996) , 10.1073/PNAS.93.18.9821